by Nick Veringmeier | Oct 4, 2026
Vanishing White Matter GuanaRep Repurposing guanabenz for Vanishing White Matter, taking an academic discovery through clinical development, pharmaceutical development and a registration pathway designed around patient access. Amsterdam UMC Guanabenz Phase I/II...
by Nick Veringmeier | Oct 4, 2026
Pseudoxanthoma elasticum Haltex Therapeutics Repurposing etidronate for PXE, building on academic clinical research and creating a registration pathway for a treatment that had effectively disappeared from the market. UMC Utrecht Etidronate EMA orphan designation...
by Nick Veringmeier | Oct 4, 2026
Alzheimer's disease Salz Biosciences Repurposing existing bisphosphonates for Alzheimer's disease, using brain-penetration and proteomic data to select promising candidates and create a route into clinical development. Groningen Bisphosphonates PCT application filed...
by Nick Veringmeier | Oct 4, 2026
Cystinosis Patient One Developing PO-003, a sustained-release cysteamine bitartrate formulation designed to reduce treatment burden while keeping cystinosis therapy accessible. Fair Medicine spin-off PO-003 Clinical development...
by Nick Veringmeier | Oct 4, 2026
href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;500;600;700;800;900&display=swap" rel="stylesheet" PROJECT SUMMARY ===================================================== --> Pancreatic cancer Pepper Therapeutics Repurposing phenformin as a potential...
